PL3122775T3 - Przeciwciała monoklonalne przeciwko czynnikowi wzrostu i różnicowania 15 (gdf-15) oraz ich zastosowanie do leczenia kacheksji nowotworowej i nowotworu - Google Patents

Przeciwciała monoklonalne przeciwko czynnikowi wzrostu i różnicowania 15 (gdf-15) oraz ich zastosowanie do leczenia kacheksji nowotworowej i nowotworu

Info

Publication number
PL3122775T3
PL3122775T3 PL15712629T PL15712629T PL3122775T3 PL 3122775 T3 PL3122775 T3 PL 3122775T3 PL 15712629 T PL15712629 T PL 15712629T PL 15712629 T PL15712629 T PL 15712629T PL 3122775 T3 PL3122775 T3 PL 3122775T3
Authority
PL
Poland
Prior art keywords
gdf
cachexia
cancer
treatment
difference
Prior art date
Application number
PL15712629T
Other languages
English (en)
Polish (pl)
Inventor
Jörg WISCHHUSEN
Markus JUNKER
Tina SCHÄFER
Dirk PÜHRINGER
Original Assignee
Julius-Maximilians-Universität Würzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB1405475.3A external-priority patent/GB2524552B/en
Priority claimed from GB1405477.9A external-priority patent/GB2524553C/en
Application filed by Julius-Maximilians-Universität Würzburg filed Critical Julius-Maximilians-Universität Würzburg
Publication of PL3122775T3 publication Critical patent/PL3122775T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Cosmetics (AREA)
PL15712629T 2014-03-26 2015-03-26 Przeciwciała monoklonalne przeciwko czynnikowi wzrostu i różnicowania 15 (gdf-15) oraz ich zastosowanie do leczenia kacheksji nowotworowej i nowotworu PL3122775T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB1405475.3A GB2524552B (en) 2014-03-26 2014-03-26 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer
GB1405477.9A GB2524553C (en) 2014-03-26 2014-03-26 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
EP15712629.3A EP3122775B1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
PCT/EP2015/056654 WO2015144855A1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer

Publications (1)

Publication Number Publication Date
PL3122775T3 true PL3122775T3 (pl) 2020-05-18

Family

ID=52745885

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15712629T PL3122775T3 (pl) 2014-03-26 2015-03-26 Przeciwciała monoklonalne przeciwko czynnikowi wzrostu i różnicowania 15 (gdf-15) oraz ich zastosowanie do leczenia kacheksji nowotworowej i nowotworu
PL19205321.3T PL3653644T3 (pl) 2014-03-26 2015-03-26 Przeciwciała monoklonalne przeciwko czynnikowi wzrostu i różnicowania 15 (gdf-15) oraz ich zastosowanie do leczenia kacheksji nowotworowej i nowotworów

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL19205321.3T PL3653644T3 (pl) 2014-03-26 2015-03-26 Przeciwciała monoklonalne przeciwko czynnikowi wzrostu i różnicowania 15 (gdf-15) oraz ich zastosowanie do leczenia kacheksji nowotworowej i nowotworów

Country Status (22)

Country Link
US (6) US20170204174A1 (enExample)
EP (3) EP4316596A3 (enExample)
JP (3) JP6865585B2 (enExample)
KR (1) KR102520978B1 (enExample)
CN (1) CN106536553B (enExample)
AU (2) AU2015238264B2 (enExample)
BR (1) BR122023027559A2 (enExample)
CY (1) CY1122456T1 (enExample)
DK (2) DK3122775T3 (enExample)
ES (2) ES2763859T3 (enExample)
FI (1) FI3653644T3 (enExample)
HR (2) HRP20231514T1 (enExample)
HU (2) HUE064573T2 (enExample)
IL (2) IL248038B (enExample)
LT (2) LT3122775T (enExample)
NZ (1) NZ724649A (enExample)
PL (2) PL3122775T3 (enExample)
PT (2) PT3122775T (enExample)
RS (1) RS59700B1 (enExample)
SI (1) SI3122775T1 (enExample)
SM (1) SMT202000064T1 (enExample)
WO (1) WO2015144855A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20231514T1 (hr) 2014-03-26 2024-03-01 Julius-Maximilians-Universität Würzburg Monoklonska antitijela za faktor rasta i diferencijacije 15 (gdf-15), te njihova uporaba za liječenje tumorske kaheksije i raka
HUE054670T2 (hu) 2014-09-25 2021-09-28 Aveo Pharmaceuticals Inc Módszer cachexia visszafordítására és túlélés megnövelésére egy GDF15 modulátor és egy rákellenes szer adagolásával
GB201517528D0 (en) * 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
ES2968226T3 (es) 2015-10-02 2024-05-08 Univ Wuerzburg J Maximilians GDF-15 como marcador de diagnóstico para predecir la evolución clínica de un tratamiento con bloqueadores de puntos de control inmunitario
US11464856B2 (en) * 2015-10-02 2022-10-11 Julius-Maximilians-Universität Würzburg Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers
CN109071647B (zh) * 2016-04-27 2022-11-22 诺华股份有限公司 抗生长分化因子15的抗体及其用途
NZ750244A (en) * 2016-07-06 2025-11-28 Nat Res Council Canada Humanized antibodies transmigrating the blood-brain barrier and uses thereof
US20190234935A1 (en) * 2016-10-12 2019-08-01 Janssen Biotech, Inc. Methods for screening for modulators of gdf15-like biological activity
JP7134960B2 (ja) * 2016-12-06 2022-09-12 セントビンセンツ ホスピタル シドニー リミテッド 肥満及び摂食障害の治療
JP7155403B2 (ja) * 2018-08-20 2022-10-18 ファイザー・インク 抗ｇｄｆ１５抗体、組成物および使用の方法
CA3200687A1 (en) 2020-11-10 2022-05-19 Catalym Gmbh Anti-gdf15 antibody and a dosage regimen for the treatment of cancer
EP4314071A1 (en) 2021-03-31 2024-02-07 Cambridge Enterprise Limited Therapeutic inhibitors of gdf15 signalling
AU2022328390A1 (en) 2021-08-10 2024-03-21 Adimab, Llc Anti-gdf15 antibodies, compositions and uses thereof
US20250382359A1 (en) 2021-12-22 2025-12-18 Byomass Inc. Targeting gdf15-gfral pathway
US20250092124A1 (en) * 2022-01-26 2025-03-20 Yunnan Baiyao Group Co., Ltd. Antibody molecule against growth and differentiation factor 15 and use thereof
CN119487065A (zh) 2022-05-09 2025-02-18 舒泰神（北京）生物制药股份有限公司 特异性识别gdf15的抗体及其应用
CN116462757A (zh) * 2023-03-24 2023-07-21 科兴生物制药股份有限公司 Gdf15的单域抗体及其应用
CN118878677A (zh) * 2024-09-29 2024-11-01 江苏凯基生物技术股份有限公司 一种IgM亚型单克隆抗体及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6465181B2 (en) 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
EP1179067B1 (en) 1999-05-17 2006-12-13 BIOPHARM Gesellschaft zur biotechnologischen Entwicklung und zum Vertrieb von Pharmaka mbH Neuroprotective properties of gdf-15, a member of the tgf-beta superfamily
US7141661B2 (en) 2000-09-08 2006-11-28 The United States Of America As Represented By The Department Of Health And Human Services Non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
SI1704166T1 (sl) * 2004-01-07 2015-06-30 Novartis Vaccines And Diagnostics, Inc. M-scf specifiäśno monoklonsko protitelo in uporabe le-tega
CA2561877C (en) 2004-04-13 2017-03-14 St. Vincent's Hospital Sydney Limited Use of mic-1 or modulating agent thereof to modulate appetite or body weight
US20100278843A1 (en) 2007-08-16 2010-11-04 St. Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
AU2008310310A1 (en) * 2007-10-09 2009-04-16 St Vincent's Hospital Sydney Limited A method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1
JP5581323B2 (ja) 2008-09-29 2014-08-27 ロシュ グリクアート アクチェンゲゼルシャフト ヒトｉｌ１７に対する抗体およびその使用
US20120309697A1 (en) 2009-10-28 2012-12-06 Samuel Norbert Breit Methods of diagnosing and prognosing colonic polyps
US9212221B2 (en) * 2010-03-03 2015-12-15 Detroit R & D, Inc. Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
KR101398363B1 (ko) * 2010-11-17 2014-05-22 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN102321173B (zh) 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
EP2565262A1 (en) 2011-08-31 2013-03-06 VTU Holding GmbH Protein expression
JP2015506373A (ja) 2012-01-26 2015-03-02 アムジエン・インコーポレーテツド 成長分化因子１５（ｇｄｆ−１５）ポリペプチド
KR101838786B1 (ko) * 2012-09-26 2018-03-15 율리우스-막시밀리안스 우니버지태트 뷔르츠부르크 성장 및 분화 인자 15 (gdf-15)에 대한 모노클로날 항체
EP2934584B1 (en) 2012-12-21 2020-02-19 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
HRP20231514T1 (hr) 2014-03-26 2024-03-01 Julius-Maximilians-Universität Würzburg Monoklonska antitijela za faktor rasta i diferencijacije 15 (gdf-15), te njihova uporaba za liječenje tumorske kaheksije i raka

Also Published As

Publication number Publication date
AU2020260440A1 (en) 2020-11-26
EP3653644B1 (en) 2023-11-15
US20200308264A1 (en) 2020-10-01
NZ724649A (en) 2022-07-01
AU2015238264B2 (en) 2020-09-03
CN106536553A (zh) 2017-03-22
EP4316596A2 (en) 2024-02-07
RS59700B1 (sr) 2020-01-31
KR102520978B1 (ko) 2023-04-11
LT3653644T (lt) 2024-01-25
JP2023098966A (ja) 2023-07-11
DK3653644T5 (da) 2024-08-26
HUE047398T2 (hu) 2020-04-28
EP3653644A1 (en) 2020-05-20
JP2017508475A (ja) 2017-03-30
US10604565B2 (en) 2020-03-31
HUE064573T2 (hu) 2024-03-28
FI3653644T3 (fi) 2023-12-12
LT3122775T (lt) 2020-02-10
EP3122775A1 (en) 2017-02-01
IL248038B (en) 2020-08-31
EP4316596A3 (en) 2024-04-17
SI3122775T1 (sl) 2020-02-28
CN106536553B (zh) 2021-03-12
US11634482B2 (en) 2023-04-25
BR112016022013A2 (pt) 2017-10-31
HRP20231514T1 (hr) 2024-03-01
IL276405A (en) 2020-09-30
US20180298091A1 (en) 2018-10-18
HRP20200034T1 (hr) 2020-03-20
PT3653644T (pt) 2023-12-19
EP3122775B1 (en) 2019-11-13
PT3122775T (pt) 2019-12-26
WO2015144855A1 (en) 2015-10-01
US20230382987A1 (en) 2023-11-30
IL248038A0 (en) 2016-11-30
DK3653644T3 (da) 2023-12-18
AU2015238264A1 (en) 2016-10-20
KR20160139005A (ko) 2016-12-06
IL276405B (en) 2021-07-29
JP7607498B2 (ja) 2024-12-27
DK3122775T3 (da) 2020-02-03
US20200308265A1 (en) 2020-10-01
US11760795B2 (en) 2023-09-19
US20170204174A1 (en) 2017-07-20
ES2763859T3 (es) 2020-06-01
CA2943694A1 (en) 2015-10-01
JP6865585B2 (ja) 2021-04-28
AU2020260440B2 (en) 2024-03-21
CY1122456T1 (el) 2021-01-27
SMT202000064T1 (it) 2020-03-13
PL3653644T3 (pl) 2024-03-04
US20260008841A1 (en) 2026-01-08
ES2965626T3 (es) 2024-04-16
BR122023027559A2 (pt) 2024-01-30
JP2021119138A (ja) 2021-08-12

Similar Documents

Publication Publication Date Title
PL3122775T3 (pl) Przeciwciała monoklonalne przeciwko czynnikowi wzrostu i różnicowania 15 (gdf-15) oraz ich zastosowanie do leczenia kacheksji nowotworowej i nowotworu
IL294982B1 (en) nk-2 cells and genetically engineered monoclonal antibodies for cancer treatment
IL272470A (en) Methods and materials for assessing and treating cancer
IL269150A (en) Compositions and methods for treating cancer
IL267803A (en) Methods for treating cancer with anti-tim-3 antibodies
HUE053452T2 (hu) Anti-PD-1 és anti-LAG3 antitestek rák kezelésére
IL264674B1 (en) Antibodies to siglec7 for cancer treatment
PL3601358T3 (pl) Przeciwciała anty-trem2 i sposoby ich wykorzystania
IL268814A (en) Compositions and methods for treatment of cancer
IL258955A (en) Compositions and methods for treatment of cancer
IL263224A (en) Methods and compositions for treating cancers
IL253462A0 (en) Cancer treatment with monoclonal antibodies against latency-associated peptide
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
IL286208A (en) Humanized influenza monoclonal antibodies and methods of use thereof
SG11201705585QA (en) Anti-myostatin antibodies and methods of use
IL271260A (en) Multi-specific antibodies and methods of making and using thereof
DK3508502T3 (da) Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer
DK3826667T3 (da) Claudin6-antistoffer og fremgangsmåder til behandling af kræft
IL271257A (en) Multi-specific antibodies and methods of making and using thereof
PL3280440T3 (pl) Humanizowane przeciwciała anty-c1s i sposoby ich zastosowania
IL269157A (en) Compositions and methods for treating cancer
IL282478A (en) Materials and methods for treating cancer
IL272147A (en) Methods and compositions for the treatment of cancer
GB2524553B (en) Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
IL256763A (en) Compositions and methods for treating cancer